2018 American Transplant Congress
Graft Dendritic Cell p40 Homodimers Activate Donor-Reactive Endogenous Memory CD8 T Cells within Higher Risk Allografts
Immunology, Cleveland Clinic, Cleveland, OH.
Memory T cells with donor-reactivity pose a major barrier to successful allograft transplantation and tolerance induction. Longer cold ischemic storage (CIS) prior to transplantation promotes…2018 American Transplant Congress
p40 Homodimer Induced Proliferation of Endogenous Donor-Reactive Memory CD8 T Cells within High Risk Allografts Requires Memory CD8 T Cell Expression of CD122
Immunology, Cleveland Clinic, Cleveland, OH.
Increasing the duration of cold ischemic storage (CIS) from 0.5 to 8 hrs prior to transplant induces the increased proliferation of endogenous donor-reactive CD4 and…2018 American Transplant Congress
The BEST Trial: A Prospective Randomized Multicenter Trial of Belatacept-Based CNI- and Corticosteroid-Free Immunosuppression
Previous large multicenter belatacept (BELA)-based CNI- and steroid-free immunosuppressive trials have not enrolled to completion due to safety concerns. The BEST Trial (Belatacept-based Early Steroid…2018 American Transplant Congress
Late Conversion from Calcineurin Inhibitors to Belatacept is Associated with a Sustained Improvement in Kidney Allograft Function
Medicine/Nephrology, Cedars Sinai Medical Center, Los Angeles, CA.
Introduction: Belatacept was shown to have longer kidney graft survival and higher eGFR at 7 years than a calcineurin inhibitor (CNI)-based regimen in the BENEFIT…2018 American Transplant Congress
Clinical Outcomes of Conversion from Calcineurin Inhibitor to Belatacept-Based Immunosuppression in Highly Sensitized Kidney Transplant Recipients
Cedars Sinai Medical Center, Los Angeles.
Introduction:Efficacy of belatacept when converted from calcineurin inhibitors (CNI) in high immunologic risk patients has not been established. We examined the impact of HLA-sensitization on…2018 American Transplant Congress
Presence of Chronic Vascular Lesions on Allograft Biopsy is Associated with Greater Improvement in Renal Function after Conversion from Tacrolimus to Belatacept
Background: Conversion from tacrolimus to belatacept has been shown to be beneficial for an increasing number of kidney transplant (KT) patients. However, predicting factors for…2018 American Transplant Congress
Precision Medicine for Determining the Efficacy of a Novel Belatacept Regimen
Transplant Nephrology, UCSF, San Francisco, CA.
IntroBelatacept is increasingly used as maintenance immunosuppression to improve long term outcomes in kidney transplant. Since acute rejection in patients on belatacept have been noted…2018 American Transplant Congress
Cognition after Belatacept Conversion
Yale University, New Haven, CT.
Intro: Kidney Transplant Recipients (KTRs) taking calcineurin inhibitors (CNIs) can experience varying drug toxicities. Less well studied compared to the metabolic consequences, many patients report…2018 American Transplant Congress
Metabolic Therapy as a Platform for CTLA4Ig Costimulation Blockade in Preventing Allograft Rejection
The backbone of current immunosuppression regimens remains calcineurin inhibitors (CNI) in association with steroids, mycophenolate mofetil or mTOR inhibitors. However, their long-term administration is associated…2018 American Transplant Congress
Urinary CXCL9 Monitoring to Accompany a Safe CNI-to-Belatacept Conversion in Kidney Transplant Patients
Background: Converting renal transplant recipients from CNI to belatacept immunosuppression has been proposed as a strategy to limit nephrotoxicity, but it is associated with an…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 30
- Next Page »